Clinical, pathological and genetic characteristics of Perry disease—new cases and literature review. (26th August 2021)

• Record Type: Journal Article
• Authors: Dulski, Jarosław; Cerquera‐Cleves, Catalina; Milanowski, Lukasz; Kidd, Alexa; Sitek, Emilia J.; Strongosky, Audrey; Vanegas Monroy, Ana María; Dickson, Dennis W.; Ross, Owen A.; Pentela‐Nowicka, Jolanta; Sławek, Jarosław; Wszolek, Zbigniew K.
• Is Part Of: European journal of neurology. Volume 28:Number 12(2021)
• Page Start: 4010
• Page End: 4021
• Publication Date: 2021-08-26
• Subjects: DCTN1 gene -- dynactin -- neurodegenerative disorder -- parkinsonism -- TDP‐43; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.15048
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract: Background and purpose: Perry disease (or Perry syndrome) is an autosomal dominant neurodegenerative disorder characterized by parkinsonism, neuropsychiatric symptoms, central hypoventilation, weight loss and distinct TDP‐43 pathology. It is caused by mutations of the DCTN1 gene encoding an essential component of axonal transport. The objectives were to provide the current state of knowledge on clinical, pathological and genetic aspects of Perry disease, as well as practical suggestions for the management of the disease. Methods: Data on new patients from New Zealand, Poland and Colombia were collected, including autopsy report. Also all of the published papers since the original work by Perry in 1975 were gathered and analyzed. Results: Parkinsonism was symmetrical, progressed rapidly and was poorly responsive to L‐Dopa; nonetheless, a trial with high doses of L‐Dopa is warranted. Depression was severe, associated with suicidal ideations, and benefited from antidepressants and L‐Dopa. Respiratory symptoms were the leading cause of death, and artificial ventilation or a diaphragm pacemaker prolonged survival. Weight loss occurred in most patients and was of multifactorial etiology. Autonomic dysfunction was frequent but underdiagnosed. There was a clinical overlap with other neurodegenerative disorders. An autopsy showed distinctive pallidonigral degeneration with TDP‐43 pathology. Genetic testing provided evidence of a common founder for two families. There was striking phenotypic variability in DCTN1 ‐related disorders. It is hypothesized that oligogenic or polygenic inheritance is at play. Conclusions: Perry disease and other DCTN1 ‐related diseases are increasingly diagnosed worldwide. Relatively effective symptomatic treatments are available. Further studies are needed to pave the way toward curative/gene therapy. Abstract : Perry disease (or Perry syndrome) is an increasingly recognized worldwide hereditary neurodegenerative disorder. This paper adds to the growing body of research on the Perry disease by presenting new data on patients from different parts of the world, compiling all of the reported cases in the literature and discussing the current state of knowledge of the disease; future research directions are presented.